Neuphoria Therapeutics Inc.
NASDAQ Global MarketTotal Valuation
Neuphoria Therapeutics Inc. carries a market capitalization of 18.05M, placing it among publicly traded companies globally. Its enterprise value stands at -2.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 18.05M |
| Enterprise Value | -2.75M |
Share Statistics
Neuphoria Therapeutics Inc. currently has 1.85M shares outstanding.
| Shares Outstanding | 1.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Neuphoria Therapeutics Inc. trades at a trailing price-to-earnings ratio of 2.42. The price-to-sales ratio is 0.90, and the price-to-book ratio stands at -0.08.
| PE Ratio | 2.42 |
| PS Ratio | 0.90 |
| PB Ratio | -0.08 |
| P/TBV Ratio | 1.12 |
| P/FCF Ratio | 21.67 |
| P/OCF Ratio | 21.67 |
Enterprise Valuation
| EV / Sales | 6.92 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Neuphoria Therapeutics Inc. maintains a current ratio of 11.01, meaning it holds 11.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.01 |
| Quick Ratio | 11.00 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 0.90 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | 164.45 |
| Return on Assets (ROA) | 37.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -235,880.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Neuphoria Therapeutics Inc.'s stock has declined approximately -56.62338% over the past 52 weeks. The 50-day moving average sits at 4.45, while the 200-day moving average is 5.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -56.62338% |
| 50-Day Moving Average | 4.45 |
| 200-Day Moving Average | 5.28 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Neuphoria Therapeutics Inc. generated 15.66M in revenue and converted that into 5.83M in net income, yielding earnings per share of 3.80. EBITDA reached 192,269.00, while operating income came in at -470,681.00.
| Revenue | 15.66M |
| Gross Profit | N/A |
| Operating Income | -470,681.00 |
| Pretax Income | 5.59M |
| Net Income | 5.83M |
| EBITDA | 192,269.00 |
| EBIT | -470,681.00 |
| Earnings Per Share (EPS) | 3.80 |
Balance Sheet
Neuphoria Therapeutics Inc. holds 17.04M in cash and equivalents against 172,460.00 in total debt, resulting in a net debt position of -17.01M. Total book value stands at -169.46M, with working capital of 15.54M providing operational flexibility.
| Cash & Cash Equivalents | 17.04M |
| Total Debt | 172,460.00 |
| Net Debt | -17.01M |
| Equity (Book Value) | -169.46M |
| Book Value Per Share | -110.65 |
| Working Capital | 15.54M |
Cash Flow
Neuphoria Therapeutics Inc. produced 651,512.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | 651,512.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | 651,512.00 |
| FCF Per Share | 0.43 |
Margins
Neuphoria Therapeutics Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3.01 and net profit margin of 37.20 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -3.01 |
| Pretax Margin | 35.70 |
| Profit Margin | 37.20 |
| EBITDA Margin | 1.23 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -56.26 |
| FCF Yield | 4.61 |
Stock Splits
Neuphoria Therapeutics Inc.'s most recent stock split took place on December 24, 2024 with a 12:1 split ratio.
| Last Split Date | 12/24/2024 |
| Split Ratio | 12:1 |
Scores
Neuphoria Therapeutics Inc. posts an Altman Z-Score of -10.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -10.03 |